Sabin Vaccine Institute Strengthens Ebola Sudan and Marburg Vaccines Program with Additional NIAID Partnership

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations.

Since 2011, the Sabin Vaccine Institute (Sabin) has organized a vaccinology course for immunization managers in Latin America. Launched under the direction of Dr.

Dr. John B. Robbins died on November 27, 2019 at age 86. Dr. Robbins was the 2001 recipient of the Sabin Gold Medal for his pivotal role in the development of Hib conjugate vaccine, which is now used throughout the world.

We have entered a post-antibiotic era. That striking statement comes from last week’s landmark report from the U.S. Centers for Disease Control and Prevention (CDC).

With fall in full swing, it’s time to prepare for influenza season. Though often confused with the common cold, influenza is a serious, highly contagious respiratory illness.

The success of immunization programs relies heavily on immunization program managers, who facilitate every aspect of immunization programs, from cost-effective procurement of vaccines to the vigilant monitoring of vaccine safety and efficacy. Sabin’s IAIM Network is the largest international network of immunization managers, offering opportunities to connect, share knowledge and strengthen skills required to effectively implement immunization programs.

The Sabin Vaccine Institute (Sabin) was founded 25 years ago in memory of Dr. Albert Sabin, inventor of the oral polio vaccine. Today, in recognition of World Polio Day, we are highlighting the voices of those who carry on his life’s work of advancing and advocating for science. 

Pages